DK1117437T3 - Anvendelse af forbindelser, der reducerer alfa2-antiplasmin in vivo, til fremstilling af en sammensætning til behandling af iskæmiske slagtilfælde - Google Patents

Anvendelse af forbindelser, der reducerer alfa2-antiplasmin in vivo, til fremstilling af en sammensætning til behandling af iskæmiske slagtilfælde

Info

Publication number
DK1117437T3
DK1117437T3 DK99948942T DK99948942T DK1117437T3 DK 1117437 T3 DK1117437 T3 DK 1117437T3 DK 99948942 T DK99948942 T DK 99948942T DK 99948942 T DK99948942 T DK 99948942T DK 1117437 T3 DK1117437 T3 DK 1117437T3
Authority
DK
Denmark
Prior art keywords
treatment
antiplasmin
ischemic stroke
vivo
compounds
Prior art date
Application number
DK99948942T
Other languages
Danish (da)
English (en)
Inventor
Desire Jose Collen
Nobuo Nagai
Original Assignee
Leuven Res & Dev Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99202004A external-priority patent/EP1062953A1/de
Application filed by Leuven Res & Dev Vzw filed Critical Leuven Res & Dev Vzw
Application granted granted Critical
Publication of DK1117437T3 publication Critical patent/DK1117437T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
DK99948942T 1998-09-29 1999-09-24 Anvendelse af forbindelser, der reducerer alfa2-antiplasmin in vivo, til fremstilling af en sammensætning til behandling af iskæmiske slagtilfælde DK1117437T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98203280 1998-09-29
EP99202004A EP1062953A1 (de) 1999-06-22 1999-06-22 Verwendung von Verbindungen, die Alpha2-Antiplasmin in vivo reduzieren, zur Herstellung einer Zusammensetzung zur Behandlung ischämischer Schlaganfälle
PCT/EP1999/007405 WO2000018436A1 (en) 1998-09-29 1999-09-24 Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke

Publications (1)

Publication Number Publication Date
DK1117437T3 true DK1117437T3 (da) 2007-04-10

Family

ID=26150731

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99948942T DK1117437T3 (da) 1998-09-29 1999-09-24 Anvendelse af forbindelser, der reducerer alfa2-antiplasmin in vivo, til fremstilling af en sammensætning til behandling af iskæmiske slagtilfælde

Country Status (12)

Country Link
US (1) US6946438B1 (de)
EP (1) EP1117437B1 (de)
JP (1) JP4577992B2 (de)
CN (1) CN1191856C (de)
AT (1) ATE349226T1 (de)
AU (1) AU6200599A (de)
CA (1) CA2344317C (de)
DE (1) DE69934595T2 (de)
DK (1) DK1117437T3 (de)
ES (1) ES2276536T3 (de)
HK (1) HK1041449B (de)
WO (1) WO2000018436A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1343903T3 (da) * 2000-12-21 2008-03-10 Thrombogenics Nv En gærekspressionsvektor og en fremgangsmåde til fremstilling af et rekombinant protein ved ekspression i en gærcelle
US7479270B2 (en) 2002-07-23 2009-01-20 Vegenics Limited Methods and compositions for activating VEGF-D and VEGF-C
MXPA06012236A (es) * 2004-04-22 2007-01-31 Talecris Biotherapeutics Inc Plasmina modificada en forma recombinante.
JP5539896B2 (ja) * 2007-11-29 2014-07-02 グリフオルス・セラピユーテイクス・インコーポレーテツド 組換え的に改変されたプラスミン
NZ589557A (en) * 2008-06-04 2012-08-31 Talecris Biotherapeutics Inc Immobilised streptokinase, method and kit for preparing plasmin
RU2372086C1 (ru) * 2008-08-06 2009-11-10 Илья Николаевич Медведев СПОСОБ НОРМАЛИЗАЦИИ УРОВНЯ α2 АНТИПЛАЗМИНА ПРИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ С НАРУШЕНИЕМ ТОЛЕРАНТНОСТИ К ГЛЮКОЗЕ
HUE025670T2 (en) 2009-03-03 2016-04-28 Grifols Therapeutics Inc A method for producing plasminogen
EP2451835A1 (de) 2009-07-10 2012-05-16 ThromboGenics N.V. Varianten von plasminogen und plasmin
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
RU2604807C2 (ru) 2011-01-05 2016-12-10 ТромбоДженикс НВ Варианты плазминогена и плазмина
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
WO2013036596A2 (en) 2011-09-06 2013-03-14 Reed Guy L Serpinf2-binding molecules and methods of use
US11338022B2 (en) 2015-12-18 2022-05-24 Talengen International Limited Method for preventing and treating angiocardiopathy
TWI624267B (zh) 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備預防或治療糖尿病性視網膜病變的藥劑上的用途及包括纖溶酶原用於預防或治療糖尿病性視網膜病變之藥劑
JP6793748B2 (ja) 2015-12-18 2020-12-02 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 放射性および化学的損傷を予防及び治療するための方法
TWI653981B (zh) * 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
JP6876066B2 (ja) 2015-12-18 2021-05-26 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 子宮膣部びらんを予防及び治療するための方法
CN106890325A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
CN108778307A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
US11129880B2 (en) 2016-12-15 2021-09-28 Talengen International Limited Method for promoting insulin secretion
WO2021072404A1 (en) * 2019-10-10 2021-04-15 University Of Kentucky Research Foundation A machine learning algorithm for predicting clinical outcomes and identifying drug targets in ischemic stroke
CN117677715B (zh) * 2021-07-28 2025-09-26 北京沙东生物技术有限公司 一种骨髓瘤生物标志物serpinf2及其应用
CN114736948B (zh) * 2022-06-10 2022-11-08 深圳市帝迈生物技术有限公司 一种α2-抗纤溶酶活性测定试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
CA2266339A1 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin

Also Published As

Publication number Publication date
DE69934595T2 (de) 2007-10-04
EP1117437A1 (de) 2001-07-25
ES2276536T3 (es) 2007-06-16
ATE349226T1 (de) 2007-01-15
EP1117437B1 (de) 2006-12-27
DE69934595D1 (de) 2007-02-08
WO2000018436A1 (en) 2000-04-06
US6946438B1 (en) 2005-09-20
CA2344317A1 (en) 2000-04-06
HK1041449A1 (en) 2002-07-12
JP2002525340A (ja) 2002-08-13
AU6200599A (en) 2000-04-17
CN1191856C (zh) 2005-03-09
CA2344317C (en) 2012-01-24
JP4577992B2 (ja) 2010-11-10
HK1041449B (zh) 2005-08-19
CN1320045A (zh) 2001-10-31

Similar Documents

Publication Publication Date Title
AU6200599A (en) Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of acomposition for the treatment of ischemic stroke
MY133996A (en) Compounds for the treatment of ischemia
TR200003011T2 (tr) Yeni dihidropirimidinler.
FR2627696B1 (fr) Nouvelle forme galenique du fenofibrate
BR0215405A (pt) Composições e processos de uso de collajolie
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
TR200001203T2 (tr) Yeni birleşik maddeler
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
PE20020802A1 (es) COMPUESTO DE LACTAMA COMO INHIBIDOR DE LA LIBERACION DEL PEPTIDO ß-AMILOIDE
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
IL153014A0 (en) Barbituric acid analogs as therapeutic agents
ATE429210T1 (de) Orale flüssige zusammensetzungen
DZ2936A1 (fr) Composition nouvelle à libération modifiée pour letraitement du diabète.
AU2002220715A1 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
ATE368023T1 (de) Hydroxydiphenyletherverbindungen
GB0111186D0 (en) Novel compounds
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
IT1293778B1 (it) 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
DE59806371D1 (de) Kontrastmittel für das infarkt- und nekroseimaging
SE9901077D0 (sv) Novel use
NO983530D0 (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
SE9804212D0 (sv) Compounds
SE9801494D0 (sv) Novel use
TR200504091T2 (tr) (7alfa,17alfa)-17-hidroksi-7-metil-19-nor-17-pregn-5(10)-en 20-in-3-on içeren yüksek saflıkta bileşim.
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.